Liver Cancer Trial, Recruiting NCT07327489 Sponsor: Elephas Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT07327489
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to agree to take part in the trial by giving their consent.
  • People who are 18 years of age or older at the time they give consent.
  • People who have a suspected or confirmed cancer diagnosis that a doctor has recommended investigating with a biopsy (a procedure to remove a small sample of tissue for testing).
  • People who are newly diagnosed or have a suspected cancer and have not yet received any treatment for it, or people who have had previous cancer treatment and are due to have a biopsy before starting a new round of treatment.

Who may not be able to join:

  • People who have a known autoimmune disease (where the immune system attacks the body), a history of organ transplant, or a long-term kidney or liver condition that would make them ineligible for a type of cancer treatment called immunotherapy.
  • People whose immune systems are severely weakened — for example, those taking medications that suppress the immune system, people who are HIV-positive and on antiviral medications, or people who have had an organ transplant.
  • People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Elephas
Registry
ClinicalTrials.gov
Start date
14 April 2025
Est. completion
1 April 2035

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Predicting In-Vivo Clinical Response to Immune Checkpoint Inhibitors & Researching Mechanisms of Tumor Cutting and Imaging

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov